CO6150134A2 - 18-metil-19-nor-androst-4en-17 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones framaceuticas que las contienen - Google Patents
18-metil-19-nor-androst-4en-17 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones framaceuticas que las contienenInfo
- Publication number
- CO6150134A2 CO6150134A2 CO08137168A CO08137168A CO6150134A2 CO 6150134 A2 CO6150134 A2 CO 6150134A2 CO 08137168 A CO08137168 A CO 08137168A CO 08137168 A CO08137168 A CO 08137168A CO 6150134 A2 CO6150134 A2 CO 6150134A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- espirox
- methyl
- methylene
- metil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- 18-Metil-15ß, 16ß-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general I fórmula Ien dondeZ es un átomo de oxígeno, dos átomos de hidrógeno, un grupo =NOR o NNHSO2R, en donde R es un átomo de hidrógeno o un grupo alquilo de cadena lineal o ramificada con 1 a 4, o bien, 3 a 4 átomos de carbono, R4 es un átomo de hidrógeno, un átomo de halógeno o un grupo trifluorometilo, y R6 y/o R7 pueden estar en posición a o ß, y R6 y R7 son, de modo independiente entre sí, un átomo de hidrógeno o un grupo alquilo de cadena lineal o ramificada con 1 a 4, o bien, 3 a 4 átomos de carbono o un grupo alquenilo de cadena lineal o ramificada con 2 a 4, o bien, 3 a 4 átomos de carbono o un grupo cicloalquilo saturado con 3 a 5 átomos de carbono o son juntos un grupo metileno o un doble enlace. 2.- 18-Metil-15ß, 16ß-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general I, caracterizadas en que Z es un átomo de oxígeno. 3.- 18-Metil-15ß, 16ß-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general I, caracterizadas en que es un átomo de hidrógeno, un grupo metilo o un átomo de cloro. 4.- 18-Metil-15ß, 16ß-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general I, caracterizadas en que R6 y R7 son juntos un grupo 5a, 6a o 5ß, 6ß o un enlace adicional. 5.- 18-Metil-15ß, 16ß-metilen-19-nor-20-espirox-4-en-3-onas de la fórmula general I, caracterizadas en que R7 es un grupo a- o ß- metilo-, etilo-, propilo- o etenilo o un residuo a- o ß- ciclopropilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006030416A DE102006030416A1 (de) | 2006-06-29 | 2006-06-29 | 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6150134A2 true CO6150134A2 (es) | 2010-04-20 |
Family
ID=38626491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO08137168A CO6150134A2 (es) | 2006-06-29 | 2008-12-26 | 18-metil-19-nor-androst-4en-17 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones framaceuticas que las contienen |
Country Status (41)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007063496A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102007063498A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| DE102008026793A1 (de) | 2008-06-02 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
| WO2010066354A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
| WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
| KR20150005548A (ko) | 2012-04-23 | 2015-01-14 | 바이엘 파마 악티엔게젤샤프트 | 월경과다증의 치료에서의 18-메틸-15β,16β-메틸렌-19-노르-20-스피록스-4-엔-3-온 시스템의 용도, 및 자궁 출혈 장애의 치료를 위한 18-메틸-15β,16β-메틸렌-19-노르-20-스피록스-4-엔-3-온을 함유하는 자궁내 시스템 |
| TW201350122A (zh) * | 2012-04-23 | 2013-12-16 | Bayer Pharma AG | １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途 |
| WO2015055789A1 (en) * | 2013-10-17 | 2015-04-23 | Bayer Pharma Aktiengesellschaft | INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION |
| PE20160534A1 (es) * | 2013-10-18 | 2016-06-15 | Bayer Oy | Sistema de administracion intrauterina |
| CN105237605B (zh) * | 2014-07-11 | 2019-01-25 | 上海迪赛诺生物医药有限公司 | 一种用于合成孕二烯酮的中间体及其制备方法和应用 |
| CN109575094B (zh) * | 2019-01-17 | 2021-01-26 | 浙江仙琚制药股份有限公司 | 替勃龙中间体的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3798213A (en) * | 1971-01-25 | 1974-03-19 | Merck & Co Inc | 7 alpha-methyl-20-spiroxane-3-ones and process |
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
| DE3111950A1 (de) | 1981-03-23 | 1982-09-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| DE3402329A1 (de) * | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| EP1148061B1 (en) | 1996-12-11 | 2007-10-17 | G.D. Searle LLC. | Epoxidation process |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| US8445469B2 (en) * | 2004-12-30 | 2013-05-21 | Bayer Intellectual Property Gmbh | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter |
| DE102004063864A1 (de) * | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
-
2006
- 2006-06-29 DE DE102006030416A patent/DE102006030416A1/de not_active Withdrawn
-
2007
- 2007-06-28 US US11/769,952 patent/US7846917B2/en not_active Expired - Fee Related
- 2007-06-29 WO PCT/EP2007/005893 patent/WO2008000521A1/de active Application Filing
- 2007-06-29 DK DK07765033.1T patent/DK2038294T3/da active
- 2007-06-29 PL PL07765033T patent/PL2038294T3/pl unknown
- 2007-06-29 RU RU2009102772/04A patent/RU2440365C2/ru not_active IP Right Cessation
- 2007-06-29 CA CA2656443A patent/CA2656443C/en not_active Expired - Fee Related
- 2007-06-29 AT AT07765033T patent/ATE490967T1/de active
- 2007-06-29 ES ES07765033T patent/ES2357698T3/es active Active
- 2007-06-29 TW TW096123940A patent/TWI413645B/zh not_active IP Right Cessation
- 2007-06-29 PT PT07765033T patent/PT2038294E/pt unknown
- 2007-06-29 NZ NZ573951A patent/NZ573951A/en not_active IP Right Cessation
- 2007-06-29 SI SI200730533T patent/SI2038294T1/sl unknown
- 2007-06-29 DE DE502007005902T patent/DE502007005902D1/de active Active
- 2007-06-29 AR ARP070102908A patent/AR061736A1/es not_active Application Discontinuation
- 2007-06-29 RS RS20110109A patent/RS51722B/en unknown
- 2007-06-29 BR BRPI0713934-9A patent/BRPI0713934A2/pt not_active IP Right Cessation
- 2007-06-29 CL CL200701919A patent/CL2007001919A1/es unknown
- 2007-06-29 UA UAA200900433A patent/UA94952C2/uk unknown
- 2007-06-29 MX MX2009000082A patent/MX2009000082A/es active IP Right Grant
- 2007-06-29 CN CN2007800246245A patent/CN101511857B/zh not_active Expired - Fee Related
- 2007-06-29 UY UY30451A patent/UY30451A1/es not_active Application Discontinuation
- 2007-06-29 JP JP2009517034A patent/JP5326085B2/ja not_active Expired - Fee Related
- 2007-06-29 MY MYPI20071041A patent/MY155015A/en unknown
- 2007-06-29 KR KR1020087031791A patent/KR101440640B1/ko active IP Right Grant
- 2007-06-29 EP EP07765033A patent/EP2038294B1/de active Active
- 2007-06-29 AU AU2007263944A patent/AU2007263944B2/en not_active Ceased
- 2007-07-02 PE PE2007000837A patent/PE20080995A1/es not_active Application Discontinuation
-
2008
- 2008-12-15 IL IL195935A patent/IL195935A0/en not_active IP Right Cessation
- 2008-12-15 TN TNP2008000518A patent/TNSN08518A1/en unknown
- 2008-12-26 CO CO08137168A patent/CO6150134A2/es unknown
- 2008-12-29 EC EC2008009014A patent/ECSP089014A/es unknown
- 2008-12-29 HN HN2008001934A patent/HN2008001934A/es unknown
- 2008-12-29 DO DO2008000089A patent/DOP2008000089A/es unknown
-
2009
- 2009-01-05 CR CR10548A patent/CR10548A/es unknown
- 2009-01-22 MA MA31582A patent/MA30596B1/fr unknown
- 2009-01-28 NO NO20090459A patent/NO20090459L/no not_active Application Discontinuation
- 2009-01-28 ZA ZA200900673A patent/ZA200900673B/xx unknown
- 2009-03-05 GT GT200800307A patent/GT200800307A/es unknown
-
2010
- 2010-02-11 HK HK10101560.6A patent/HK1133659A1/xx not_active IP Right Cessation
-
2011
- 2011-03-04 HR HR20110161T patent/HRP20110161T1/hr unknown
- 2011-03-08 CY CY20111100261T patent/CY1111658T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6150134A2 (es) | 18-metil-19-nor-androst-4en-17 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones framaceuticas que las contienen | |
| CR9730A (es) | Mezclas fungicidas que contienen anilidas sustituidas de acido 1-metilpirazol-4-ilcarboxilico | |
| CL2012000284A1 (es) | Compuestos derivados de pirimidinio; y composicion que comprende dicho compuesto y al menos un agente biologicamente activo. | |
| BRPI0601217A (pt) | processo para aumentar a estabilidade à oxidação de biodiesel | |
| ATE394992T1 (de) | Lanzettensystem mit sterilschutz | |
| AR060645A1 (es) | Fibra de carbono | |
| ES2422165T3 (es) | Derivados de ciclohexilimidazol lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
| MX2008012037A (es) | Reduccion de la viscosidad. | |
| BR112013003002A2 (pt) | composição contendo aditivo polar e agente quelante útil no hidroprocessamento de suprimentos hidrocarbonetos e método de sua produção e utilização | |
| EA201170703A1 (ru) | Производные адамантилбензамида | |
| BRPI0519958A2 (pt) | branqueamento de dente | |
| BR0000654A (pt) | Preparação de composição de borracha vulcanizada com peróxido e artigos tendo ela pelo menos como um dos seus componentes | |
| UY31152A1 (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
| CR10943A (es) | Mezclas fungicidas a partir de 1-metilpirazol- 4- ilcarboxanilidas y azolopirimidinilaminas | |
| AR056455A1 (es) | Mezclas pesticidas | |
| BRPI0705971A2 (pt) | composiÇço para um prÉ-tratamento de espuma para instrumentos mÉdicos | |
| DK1987121T3 (da) | Biocid hydrogenperoxidsammensætning med forøget aktivitet | |
| GT200700057A (es) | Nuevos derivados de piridazina | |
| FR2947276B1 (fr) | Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides | |
| MY146597A (en) | Organic sulfur compound and its use for controlling harmful arthropods | |
| BRPI1007575A2 (pt) | Método para controlar micro-organismos em um sistema aquoso | |
| CR9687A (es) | Mezclas pesticidas | |
| CR11340A (es) | Mezclas fungicidas de triticonazol y difenoconazol | |
| BRPI0615384B8 (pt) | composições oftálmicas de cetotifeno estabilizadas e conservadas | |
| AR019701A1 (es) | Compuestos derivados de alfa-d-xilosa, preparacion y su utilizacion en terapeutica |